Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) generates a steady flow of news centered on its commercial performance with WAKIX (pitolisant) and the advancement of a late-stage CNS pipeline. Recent press releases highlight preliminary and reported net product revenue for WAKIX, multi-year revenue growth, and guidance updates that frame the company’s evolution as a profitable, self-funding biotech focused on rare neurological diseases.
Investors following HRMY news can track updates on WAKIX in narcolepsy, including disclosures about average treated patient numbers, franchise growth and efforts to extend the pitolisant lifecycle through next-generation formulations such as pitolisant gastro-resistant (GR) and pitolisant high dose (HD). News items also cover clinical and regulatory milestones, such as pivotal bioequivalence results for pitolisant GR, Phase 3 trial plans and timelines, and the role of these formulations in potentially expanding indications and supporting additional exclusivity.
Harmony Biosciences’ news flow also features developments in its broader pipeline. This includes initiation and progress of the Phase 1 trial for BP1.15205, an investigational orexin-2 receptor agonist for central disorders of hypersomnolence, and Phase 3 ARGUS and LIGHTHOUSE trials evaluating EPX-100 (clemizole hydrochloride) in Dravet syndrome and Lennox–Gastaut syndrome. The company reports open-label extension data suggesting clinically meaningful seizure reductions and favorable tolerability for EPX-100, as well as program status for EPX-200 and ZYN002, including the outcome of the RECONNECT study in Fragile X syndrome.
Additional HRMY news includes participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, where Harmony’s management presents commercial results, pipeline updates and strategic priorities. For investors, analysts and observers of rare neurological disease therapeutics, the HRMY news page offers a centralized view of earnings announcements, guidance changes, clinical trial readouts and portfolio decisions that shape the company’s trajectory.
Harmony Biosciences (Nasdaq: HRMY) presented post-hoc analyses of WAKIX® (pitolisant) data at the virtual SLEEP 2020 meeting, showcasing its efficacy and safety in treating narcolepsy. Key findings included significant improvements in excessive daytime sleepiness and cataplexy reduction compared to placebo, with significant time-to-response from Week 2. The analyses indicated a favorable cardiac safety profile for pitolisant, with no substantial cardiovascular risks observed. These results aim to assist healthcare professionals in treatment decisions for narcolepsy patients.
Harmony Biosciences (Nasdaq: HRMY) announced that it will present new safety and efficacy data on its narcolepsy treatment, WAKIX® (pitolisant), at the 34th Annual Meeting of the Associated Professional Sleep Societies, SLEEP 2020, from August 27-30, 2020. The presentations include findings from the Pitolisant Expanded Access Clinical Evaluation Program and analyses of pitolisant's cardiac safety profile. Harmony's Chief Medical Officer highlighted the importance of these analyses in providing important information for patients and healthcare providers.
Harmony Biosciences has completed its upsized IPO, successfully offering 6,151,162 shares of common stock at $24.00 per share, yielding gross proceeds of approximately $147.6 million. This offering included 802,325 shares sold under the underwriters' option. Shares began trading on the Nasdaq Global Market under the ticker symbol HRMY on August 19, 2020. The offering was led by Goldman Sachs, Jefferies, and Piper Sandler, with the registration statement declared effective on August 18, 2020.
Harmony Biosciences announced the pricing of its upsized initial public offering (IPO) of 5,348,837 shares at $24.00 each, aiming to raise a total of $128.4 million. The shares will start trading on the Nasdaq under the ticker symbol HRMY on August 19, 2020. An additional 802,325 shares may be purchased by underwriters within 30 days at the IPO price. This offering supports Harmony's mission of developing innovative therapies for rare neurological disorders and is expected to close on August 21, 2020, subject to customary conditions.